糖脉康颗粒联合胰岛素强化治疗2型糖尿病的临床疗效及对患者血脂和ET-1的影响

目的:探讨糖脉康颗粒联合胰岛素强化治疗2型糖尿病(type 2 diabetes mellitus,T2DM)的临床观察及对患者血脂和内皮素-1(ET-1)的影响。方法:将滨州市人民医院收治的124例T2DM患者采用随机数字表法分为对照组和观察组各62例。在常规治疗基础下,对照组给予胰岛素强化治疗,观察组在对照组治疗的基础上联合应用糖脉康颗粒治疗。比较两组患者临床疗效、血糖相关指标、血脂和血清ET-1水平及低血糖事件的发生率。结果:治疗后,观察组显效率为83.9%,显著高于对照组的67.7%(P0.05)。与对照组相比,观察组空腹血糖(fasting plasma glucose,FPG)(7.2±0.4)VS(7.9±0.5)mmol·L~(-1),餐后2 h血糖(2 h plasma glucose,2 h PG)(8.5±0.5)VS(9.4±0.6)mmol·L~(-1),糖化血红蛋白A1c(glycosylated hemoglobin A1c,Hb A1c)(7.0%±0.4%)VS(7.6%±0.5%)水平显著降低,血脂总胆固醇(total cholesterol,TC)(4.36±0.82)VS(5.21±0.94)mmol·L~(-1),甘油三酯(triglyceride,TG)(1.93±0.68)VS(2.20±0.53)mmol·L~(-1),低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C)(3.10±0.54)VS(3.90±0.64)mmol·L~(-1)水平显著降低,高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)(1.59±0.35)VS(1.29±0.32)mmol·L~(-1)水平显著升高,ET-1(70.2±7.4)VS(75.6±8.3)ng·L~(-1)水平显著降低,比较都有统计学差异(P0.05)。治疗过程中,低血糖发生率为8.1%,与对照组4.8%的发生率比较差异不显著。结论:糖脉康颗粒联合胰岛素强化治疗T2DM的临床效果可靠,能够显著提高疗效,改善血糖、血脂指标,降低ET-1水平,且不会增加低血糖等不良反应发生率,临床上值得推广使用。

Curative Observation of Tangmaikang Particles in Combination with Intensive Insulin Therapy in Treatment of Type Diabetes Mellitus and Its Effects on Blood Lipids and ET-1

Objective:To investigate the clinical effect of Tangmaikang particles in combination with intensive insulin therapy in the treatment of type 2 diabetes mellitus (T2DM) and its effects on blood lipids and endothelin-1(ET-1). Method:The 124 cases of T2DM meeting the inclusion criteria in people's hospital of Binzhou were randomly divided into control group and observation group equally. Besides conventional treatments, the control group was also treated with intensive insulin therapy, while the observation group was also treated with Tangmaikang particles combined with intensive insulin therapy. Then, the curative efficacy, glucose-related indicators, level of blood lipids, ET-1 and incidence of hypoglycemia were compared between two groups. Result:After treatment, the effective rate in the observation group was 83.9%, significantly higher than 67.7% in the control group (P<0.05). In comparison with the control group after the treatment, glucose-related indicators in observation group were as follows:fasting plasma glucose (FPG) (7.2±0.4)VS(7.9±0.5)mmol·L^-1, 2 h plasma glucose (2 hPG)(8.5±0.5)VS(9.4±0.6) mmol·L^-1, glycosylated hemoglobin A1c(HbA1c)(7.0%±0.4%)VS(7.6%±0.5%). The levels were respectively significantly lower in the observation group (all P<0.05). As to blood lipids, level of total cholesterol(TC) (4.36±0.82)VS(5.21±0.94)mmol·L^-1, triglyceride(TG)(1.93±0.68)VS(2.20±0.53)mmol·L^-1, low density lipoprotein cholesterol(LDL-C)(3.10±0.54)VS(3.90±0.64)mmol·L^-1, respectively statistically lower in the observation group. And level of high density lipoprotein cholesterol(HDL-C)(1.59±0.35)VS (1.29±0.32)mmol·L^-1was statistically higher in the observation group than that in the control group after the treatment (all P<0.05). And level of ET-1(70.2±7.4)VS(75.6±8.3) ng·L^-1 in the observation group was found statistically lower than that in the control group after the treatment (P<0.05). During the treatment, the incidence of hypoglycemia was 8.1% in the observation group and 4.8% in the control group, with no significant difference. Conclusion:Tangmaikang particles combined with intensive insulin therapy is effective for T2DM, which can significantly increase curative efficacy, improve blood glucose and blood lipids indicators and lower the level of ET-1, in addition, it would not increase the incidence of hypoglycemia, thus it is worthy for promotion in clinical use.